CAMP signaling in brain is decreased in unmedicated depressed patients and increased by treatment with a selective serotonin reuptake inhibitor

M. Fujita, Erica Richards, M. J. Niciu, D. F. Ionescu, S. S. Zoghbi, J. Hong, S. Telu, C. S. Hines, V. W. Pike, C. A. Zarate, R. B. Innis

Research output: Contribution to journalArticle

Abstract

Basic studies exploring the importance of the cyclic adenosine monophosphate (cAMP) cascade in major depressive disorder (MDD) have noted that the cAMP cascade is downregulated in MDD and upregulated by antidepressant treatment. We investigated cAMP cascade activity by using 11C-(R)-rolipram to image phosphodiesterase-4 (PDE4) in unmedicated MDD patients and after ~8 weeks of treatment with a selective serotonin reuptake inhibitor (SSRI). 11C-(R)-rolipram positron emission tomographic (PET) scans were performed in 44 unmedicated patients during a major depressive episode and 35 healthy controls. Twenty-three of the 44 patients had a follow-up 11C-(R)-rolipram PET scan ~8 weeks after treatment with an SSRI. Patients were moderately depressed (Montgomery-Åsberg Depression Rating Scale=30±6) and about half were treatment naïve. 11C-(R)-rolipram binding was measured using arterial sampling to correct for individual differences in radioligand metabolism. We found in unmedicated MDD patients widespread, ~20% reductions in 11C-(R)-rolipram binding compared with controls (P=0.001). SSRI treatment significantly increased rolipram binding (12%, P<0.001), with significantly greater increases observed in older patients (P<0.001). Rolipram binding did not correlate with severity of baseline symptoms, and increased rolipram binding during treatment did not correlate with symptom improvement. In brief, consistent with the results of basic studies, PDE4 was decreased in unmedicated MDD patients and increased after SSRI treatment. The lack of correlation between PDE4 binding and depressive symptoms could reflect the heterogeneity of the disease and/or the heterogeneity of the target, given that PDE4 has four subtypes. These results suggest that PDE4 inhibitors, which increase cAMP cascade activity, may have antidepressant effects.

Original languageEnglish (US)
Pages (from-to)754-759
Number of pages6
JournalMolecular Psychiatry
Volume22
Issue number5
DOIs
StatePublished - May 1 2017
Externally publishedYes

Fingerprint

Rolipram
Serotonin Uptake Inhibitors
Type 4 Cyclic Nucleotide Phosphodiesterase
Major Depressive Disorder
Brain
Cyclic AMP
Therapeutics
Antidepressive Agents
Phosphodiesterase 4 Inhibitors
Electrons
Depression
Individuality
Down-Regulation

ASJC Scopus subject areas

  • Molecular Biology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

Cite this

CAMP signaling in brain is decreased in unmedicated depressed patients and increased by treatment with a selective serotonin reuptake inhibitor. / Fujita, M.; Richards, Erica; Niciu, M. J.; Ionescu, D. F.; Zoghbi, S. S.; Hong, J.; Telu, S.; Hines, C. S.; Pike, V. W.; Zarate, C. A.; Innis, R. B.

In: Molecular Psychiatry, Vol. 22, No. 5, 01.05.2017, p. 754-759.

Research output: Contribution to journalArticle

Fujita, M, Richards, E, Niciu, MJ, Ionescu, DF, Zoghbi, SS, Hong, J, Telu, S, Hines, CS, Pike, VW, Zarate, CA & Innis, RB 2017, 'CAMP signaling in brain is decreased in unmedicated depressed patients and increased by treatment with a selective serotonin reuptake inhibitor', Molecular Psychiatry, vol. 22, no. 5, pp. 754-759. https://doi.org/10.1038/mp.2016.171
Fujita, M. ; Richards, Erica ; Niciu, M. J. ; Ionescu, D. F. ; Zoghbi, S. S. ; Hong, J. ; Telu, S. ; Hines, C. S. ; Pike, V. W. ; Zarate, C. A. ; Innis, R. B. / CAMP signaling in brain is decreased in unmedicated depressed patients and increased by treatment with a selective serotonin reuptake inhibitor. In: Molecular Psychiatry. 2017 ; Vol. 22, No. 5. pp. 754-759.
@article{43a0706257f94b95b7e59436c9d40c64,
title = "CAMP signaling in brain is decreased in unmedicated depressed patients and increased by treatment with a selective serotonin reuptake inhibitor",
abstract = "Basic studies exploring the importance of the cyclic adenosine monophosphate (cAMP) cascade in major depressive disorder (MDD) have noted that the cAMP cascade is downregulated in MDD and upregulated by antidepressant treatment. We investigated cAMP cascade activity by using 11C-(R)-rolipram to image phosphodiesterase-4 (PDE4) in unmedicated MDD patients and after ~8 weeks of treatment with a selective serotonin reuptake inhibitor (SSRI). 11C-(R)-rolipram positron emission tomographic (PET) scans were performed in 44 unmedicated patients during a major depressive episode and 35 healthy controls. Twenty-three of the 44 patients had a follow-up 11C-(R)-rolipram PET scan ~8 weeks after treatment with an SSRI. Patients were moderately depressed (Montgomery-{\AA}sberg Depression Rating Scale=30±6) and about half were treatment na{\"i}ve. 11C-(R)-rolipram binding was measured using arterial sampling to correct for individual differences in radioligand metabolism. We found in unmedicated MDD patients widespread, ~20{\%} reductions in 11C-(R)-rolipram binding compared with controls (P=0.001). SSRI treatment significantly increased rolipram binding (12{\%}, P<0.001), with significantly greater increases observed in older patients (P<0.001). Rolipram binding did not correlate with severity of baseline symptoms, and increased rolipram binding during treatment did not correlate with symptom improvement. In brief, consistent with the results of basic studies, PDE4 was decreased in unmedicated MDD patients and increased after SSRI treatment. The lack of correlation between PDE4 binding and depressive symptoms could reflect the heterogeneity of the disease and/or the heterogeneity of the target, given that PDE4 has four subtypes. These results suggest that PDE4 inhibitors, which increase cAMP cascade activity, may have antidepressant effects.",
author = "M. Fujita and Erica Richards and Niciu, {M. J.} and Ionescu, {D. F.} and Zoghbi, {S. S.} and J. Hong and S. Telu and Hines, {C. S.} and Pike, {V. W.} and Zarate, {C. A.} and Innis, {R. B.}",
year = "2017",
month = "5",
day = "1",
doi = "10.1038/mp.2016.171",
language = "English (US)",
volume = "22",
pages = "754--759",
journal = "Molecular Psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - CAMP signaling in brain is decreased in unmedicated depressed patients and increased by treatment with a selective serotonin reuptake inhibitor

AU - Fujita, M.

AU - Richards, Erica

AU - Niciu, M. J.

AU - Ionescu, D. F.

AU - Zoghbi, S. S.

AU - Hong, J.

AU - Telu, S.

AU - Hines, C. S.

AU - Pike, V. W.

AU - Zarate, C. A.

AU - Innis, R. B.

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Basic studies exploring the importance of the cyclic adenosine monophosphate (cAMP) cascade in major depressive disorder (MDD) have noted that the cAMP cascade is downregulated in MDD and upregulated by antidepressant treatment. We investigated cAMP cascade activity by using 11C-(R)-rolipram to image phosphodiesterase-4 (PDE4) in unmedicated MDD patients and after ~8 weeks of treatment with a selective serotonin reuptake inhibitor (SSRI). 11C-(R)-rolipram positron emission tomographic (PET) scans were performed in 44 unmedicated patients during a major depressive episode and 35 healthy controls. Twenty-three of the 44 patients had a follow-up 11C-(R)-rolipram PET scan ~8 weeks after treatment with an SSRI. Patients were moderately depressed (Montgomery-Åsberg Depression Rating Scale=30±6) and about half were treatment naïve. 11C-(R)-rolipram binding was measured using arterial sampling to correct for individual differences in radioligand metabolism. We found in unmedicated MDD patients widespread, ~20% reductions in 11C-(R)-rolipram binding compared with controls (P=0.001). SSRI treatment significantly increased rolipram binding (12%, P<0.001), with significantly greater increases observed in older patients (P<0.001). Rolipram binding did not correlate with severity of baseline symptoms, and increased rolipram binding during treatment did not correlate with symptom improvement. In brief, consistent with the results of basic studies, PDE4 was decreased in unmedicated MDD patients and increased after SSRI treatment. The lack of correlation between PDE4 binding and depressive symptoms could reflect the heterogeneity of the disease and/or the heterogeneity of the target, given that PDE4 has four subtypes. These results suggest that PDE4 inhibitors, which increase cAMP cascade activity, may have antidepressant effects.

AB - Basic studies exploring the importance of the cyclic adenosine monophosphate (cAMP) cascade in major depressive disorder (MDD) have noted that the cAMP cascade is downregulated in MDD and upregulated by antidepressant treatment. We investigated cAMP cascade activity by using 11C-(R)-rolipram to image phosphodiesterase-4 (PDE4) in unmedicated MDD patients and after ~8 weeks of treatment with a selective serotonin reuptake inhibitor (SSRI). 11C-(R)-rolipram positron emission tomographic (PET) scans were performed in 44 unmedicated patients during a major depressive episode and 35 healthy controls. Twenty-three of the 44 patients had a follow-up 11C-(R)-rolipram PET scan ~8 weeks after treatment with an SSRI. Patients were moderately depressed (Montgomery-Åsberg Depression Rating Scale=30±6) and about half were treatment naïve. 11C-(R)-rolipram binding was measured using arterial sampling to correct for individual differences in radioligand metabolism. We found in unmedicated MDD patients widespread, ~20% reductions in 11C-(R)-rolipram binding compared with controls (P=0.001). SSRI treatment significantly increased rolipram binding (12%, P<0.001), with significantly greater increases observed in older patients (P<0.001). Rolipram binding did not correlate with severity of baseline symptoms, and increased rolipram binding during treatment did not correlate with symptom improvement. In brief, consistent with the results of basic studies, PDE4 was decreased in unmedicated MDD patients and increased after SSRI treatment. The lack of correlation between PDE4 binding and depressive symptoms could reflect the heterogeneity of the disease and/or the heterogeneity of the target, given that PDE4 has four subtypes. These results suggest that PDE4 inhibitors, which increase cAMP cascade activity, may have antidepressant effects.

UR - http://www.scopus.com/inward/record.url?scp=84991013828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991013828&partnerID=8YFLogxK

U2 - 10.1038/mp.2016.171

DO - 10.1038/mp.2016.171

M3 - Article

C2 - 27725657

AN - SCOPUS:84991013828

VL - 22

SP - 754

EP - 759

JO - Molecular Psychiatry

JF - Molecular Psychiatry

SN - 1359-4184

IS - 5

ER -